nach oben

Erschienen in:

20.11.2017 | Review

Advanced Strategies for Eliminating the cccDNA of HBV

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Persistent hepatitis B virus (HBV) infection of hepatocytes is associated with a covalently closed circular DNA (cccDNA) episome. Although serologic hepatitis B surface antigen tests are negative, the presence of cccDNA is obviously increased in HBeAg-positive patients compared with that in HBeAg-negative patients, inactive carriers and patients. Moreover, trace cccDNA levels can also be found in the liver cells of patients with resolved hepatitis B infections. Therefore, clearance of cccDNA in hepatocytes could be an effective cure for HBV. In this review, we summarize the strategies that have been employed to eliminate cccDNA in recent years and discuss the future development of treatments for chronic hepatitis B.

Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol J. 2013;10:239.CrossRefPubMedPubMedCentral

Karayiannis P. Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother. 2003;51:761–785.CrossRefPubMed

Xu B, Lin L, Xu G, et al. Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2015;30:372–378.CrossRefPubMed

Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479–480:672–686.CrossRefPubMed

Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife. 2012;1:e00049.CrossRefPubMedPubMedCentral

Kock J, Rosler C, Zhang JJ, Blum HE, Nassal M, Thoma C. Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner. PLoS Pathog. 2010;6:e1001082.CrossRefPubMedPubMedCentral

Yang HC, Kao JH. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. Emerg Microb Infect. 2014;3:e64.CrossRef

Revill P, Locarnini S. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA). Curr Opin Pharmacol. 2016;30:144–150.CrossRefPubMed

Liu F, Campagna M, Qi Y, et al. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog. 2013;9:e1003613.CrossRefPubMedPubMedCentral

10.

Li HC, Huang EY, Su PY, et al. Nuclear export and import of human hepatitis B virus capsid protein and particles. PLoS Pathog. 2010;6:e1001162.CrossRefPubMedPubMedCentral

11.

Schmitz A, Schwarz A, Foss M, et al. Nucleoporin 153 arrests the nuclear import of hepatitis B virus capsids in the nuclear basket. PLoS Pathog. 2010;6:e1000741.CrossRefPubMedPubMedCentral

12.

Zlotnick A, Venkatakrishnan B, Tan Z, Lewellyn E, Turner W, Francis S. Core protein: a pleiotropic keystone in the HBV lifecycle. Antiviral Res. 2015;121:82–93.CrossRefPubMedPubMedCentral

13.

Lucifora J, Protzer U. Attacking hepatitis B virus cccDNA–The holy grail to hepatitis B cure. J Hepatol. 2016;64:S41.CrossRefPubMed

14.

Schreiner S, Nassal M. A role for the host DNA damage response in hepatitis B virus cccDNA formation—and beyond? Viruses. 2017;9:125.CrossRefPubMedCentral

15.

Baumert TF, Verrier ER, Nassal M, Chung RT, Zeisel MB. Host-targeting agents for treatment of hepatitis B virus infection. Curr Opin Virol. 2015;14:41.CrossRefPubMed

16.

Königer C, Wingert I, Marsmann M, Rösler C, Beck J, Nassal M. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci USA. 2014;111:E4244.CrossRefPubMedPubMedCentral

17.

Bock CT, Schranz P, Schroder CH, Zentgraf H. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes. 1994;8:215–229.CrossRefPubMed

18.

Pollicino T, Belloni L, Raffa G, et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology. 2006;130:823–837.CrossRefPubMed

19.

Belloni L, Pollicino T, Nicola FD, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. J Neurochem. 2002;83:19975–19979.

20.

Belloni L, Allweiss L, Guerrieri F, et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Investig. 2012;122:529–537.CrossRefPubMedPubMedCentral

21.

Lutgehetmann M, Volz T, Köpke A, et al. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology. 2010;52:16–24.CrossRefPubMed

22.

Guo JT, Pryce M, Wang X, Barrasa MI, Hu J, Seeger C. Conditional replication of duck hepatitis B virus in hepatoma cells. J Virol. 2003;77:1885.CrossRefPubMedPubMedCentral

23.

Summers J, Jilbert AR, Yang W, et al. Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci USA. 2003;100:11652.CrossRefPubMedPubMedCentral

24.

Reaichemiller GY, Thorpe M, Low HC, et al. Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing liver. Virology. 2013;446:357–364.CrossRef

25.

Allweiss L, Volz T, Giersch K, et al. Proliferation of Hepatitis B virus infected human hepatocytes induces suppression of viral replication and rapid cccDNA decrease in humanized mice. J Hepatol. 2013;58:S56–S57.CrossRef

26.

Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750–1758.CrossRefPubMed

27.

Blanpain C, Knoop C, Delforge ML, et al. Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: report on three cases and review of the literature. Transplantation. 1998;66:883–886.CrossRefPubMed

28.

Palmore TN, Shah NL, Loomba R, et al. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol. 2009;7:1130–1137.CrossRefPubMedPubMedCentral

29.

Hung HH, Su CW, Wu JC, Lee SD. Reactivation of hepatitis B virus after transarterial chemo-embolization for hepatocellular carcinoma in one patient with negative hepatitis B surface antigen. J Hepatol. 2010;52:463–465.CrossRefPubMed

30.

Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014;60:2099–2108.CrossRefPubMedPubMedCentral

31.

Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64:1972.CrossRefPubMed

32.

Lanford RE, Guerra B, Chavez D, et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology. 2013;144:1508–1517.CrossRefPubMedPubMedCentral

33.

Menne S, Tumas DB, Liu KH, et al. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. J Hepatol. 2015;62:1237–1245.CrossRefPubMedPubMedCentral

34.

Xia Y, Protzer U. Control of hepatitis B virus by cytokines. Viruses. 2017;9:18.CrossRefPubMedCentral

35.

Schluep T, Lickliter J, Hamilton J, et al. Safety, tolerability, and pharmacokinetics of ARC-520 injection, an RNA interference-based therapeutic for the treatment of chronic hepatitis B virus infection, in healthy volunteers. Clin Pharmacol Drug Dev. 2017;6(4):350–362.CrossRefPubMed

36.

Lok AS, Pan CQ, Han SH, et al. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol. 2016;65:509–516.CrossRefPubMed

37.

Mahtab MA, Akbar F, Uddin H, et al. A phase III clinical trial with a nasal vaccine containing both HBsAg and HBcAg in patients with chronic hepatitis B. J Hepatol. 2013;58:S309–S309.CrossRef

38.

Betancourt AA, Delgado CA, Estevez ZC, et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis. 2007;11:394–401.CrossRefPubMed

39.

Al-Mahtab M, Akbar SM, Aguilar JC, Uddin MH, Khan MS, Rahman S. Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B. Hepatol Int. 2013;7:981–989.CrossRefPubMed

40.

Xu DZ, Wang XY, Shen XL, et al. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol. 2013;59:450–456.CrossRefPubMed

41.

Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014;344:1221.CrossRef

42.

Xia Y, Stadler D, Lucifora J, et al. Interferon-γ and tumor necrosis factor-α produced by t cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology. 2016;150:194–205.CrossRefPubMed

43.

Bockmann JH, Xia Y, Stadler D, Protzer U. Type III interferons induce cccDNA degradation similar to type I interferons in HBV-infected HepaRG cells. Zeitschrift Für Gastroenterologie. 2015. https://doi.org/10.1055/s-0034-1397258.

44.

Qiao Y, Han X, Guan G, et al. TGF-beta triggers HBV cccDNA degradation through AID-dependent deamination. FEBS Lett. 2016;590:419–427.CrossRefPubMed

45.

Fidaa B, Olivier F, Philippe G. Interleukin 6 inhibits HBV entry through NTCP down regulation. Virology. 2015;481:34–42.CrossRef

46.

Hösel M, Quasdorff M, Wiegmann K, et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology. 2009;50:1773.CrossRefPubMed

47.

Palumbo GA, Scisciani C, Pediconi N, et al. IL6 inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome. PLoS ONE. 2015;10:e0142599.CrossRefPubMedPubMedCentral

48.

Weber ND, Stone D, Sedlak RH, et al. AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication. PLoS ONE. 2014;9:e97579.CrossRefPubMedPubMedCentral

49.

Bloom K, Ely A, Mussolino C, Cathomen T, Arbuthnot P. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther. 2013;21:1889–1897.CrossRefPubMedPubMedCentral

50.

Chen J, Zhang W, Lin J, et al. An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. Mol Ther. 2014;22:303–311.CrossRefPubMed

51.

Dreyer T, Nicholson S, Ely A, Arbuthnot P, Bloom K. Improved antiviral efficacy using TALEN-mediated homology directed recombination to introduce artificial primary miRNAs into DNA of hepatitis B virus. Biochem Biophys Res Commun. 2016;478:1563–1568.CrossRefPubMed

52.

Qi Y, Gao Z, Xu G, et al. DNA polymerase kappa is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus. PLoS Pathog. 2016;12:e1005893.CrossRefPubMedPubMedCentral

53.

Zhu W, Xie K, Xu Y, et al. CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse. Virus Res. 2016;217:125–132.CrossRefPubMed

54.

Lin SR, Yang HC, Kuo YT, et al. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol Ther Nucl Acids. 2014;3:e186.CrossRef

55.

Dong C, Qu L, Wang H, Wei L, Dong Y, Xiong S. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Res. 2015;118:110–117.CrossRefPubMed

56.

Moore MD, McGarvey MJ, Russell RA, Cullen BR, McClure MO. Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors. J Gene Med. 2005;7:918–925.CrossRefPubMed

57.

Uprichard SL, Boyd B, Althage A, Chisari FV. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci USA. 2005;102:773–778.CrossRefPubMedPubMedCentral

58.

Peng J, Zhao Y, Mai J, et al. Inhibition of hepatitis B virus replication by various RNAi constructs and their pharmacodynamic properties. J Gen Virol. 2005;86:3227–3234.CrossRefPubMed

59.

Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005;23:1002–1007.CrossRefPubMed

60.

Li G, Fu L, Jiang J, Ping Y, Huang Y, Wang Y. siRNA combinations mediate greater suppression of hepatitis B virus replication in mice. Cell Biochem Biophys. 2014;69:641–647.CrossRefPubMed

61.

Wooddell CI, Rozema DB, Hossbach M, et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther. 2013;21:973–985.CrossRefPubMedPubMedCentral

62.

Thongthae N, Payungporn S, Poovorawan Y, T-Thienprasert NP. A rational study for identification of highly effective siRNAs against hepatitis B virus. Exp Mol Pathol. 2014;97:120–127.CrossRefPubMed

63.

Sebestyen MG, Wong SC, Trubetskoy V, Lewis DL, Wooddell CI. Targeted in vivo delivery of siRNA and an endosome-releasing agent to hepatocytes. Methods Mol Biol. 2015;1218:163–186.CrossRefPubMed

64.

Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol. 2016;64:S117–131.CrossRefPubMed

65.

Gish RG, Yuen MF, Chan HL, et al. Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antiviral Res. 2015;121:97–108.CrossRefPubMed

66.

Kim JW, Lee SH, Park YS, et al. Replicative activity of hepatitis B virus is negatively associated with methylation of covalently closed circular DNA in advanced hepatitis B virus infection. Intervirology. 2011;54:316–325.CrossRefPubMed

67.

Vivekanandan P, Thomas D, Torbenson M. Hepatitis B viral DNA is methylated in liver tissues. J Viral Hepat. 2008;15:103–107.PubMed

68.

Zhang Y, Li C, Zhang Y, et al. Comparative analysis of CpG islands among HBV genotypes. PLoS ONE. 2013;8:e56711.CrossRefPubMedPubMedCentral

69.

Zhang Y, Mao R, Yan R, et al. Transcription of hepatitis B virus covalently closed circular DNA is regulated by CpG methylation during chronic infection. PLoS ONE. 2014;9:e110442.CrossRefPubMedPubMedCentral

70.

Wang H, Liu K, Fang BA, et al. Identification of acetyltransferase genes (HAT1 and KAT8) regulating HBV replication by RNAi screening. Cell Biosci. 2015;5:66.CrossRefPubMedPubMedCentral

71.

Lai CL, Wong D, Ip P, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017;66(2):275–281.CrossRefPubMed

72.

Cai D, Mills C, Yu W, et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother. 2012;56:4277–4288.CrossRefPubMedPubMedCentral

73.

Volz T, Allweiss L, Ben MM, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013;58:861.CrossRefPubMed

74.

Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology. 2014;147:48–64.CrossRefPubMed

Titel: Advanced Strategies for Eliminating the cccDNA of HBV
Publikationsdatum: 20.11.2017
Erschienen in: Digestive Diseases and Sciences / Ausgabe 1/2018
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-017-4842-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Advanced Strategies for Eliminating the cccDNA of HBV

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Wls Expression Correlates with Tumor Differentiation and TNM Stage in Hepatocellular Carcinoma

Emu Oil Improves Clinical Indicators of Disease in a Mouse Model of Colitis-Associated Colorectal Cancer

Protective Effect of 1,25-Dihydroxy Vitamin D3 on Pepsin–Trypsin-Resistant Gliadin-Induced Tight Junction Injuries

EUS-Guided Pancreatic Duct Puncture for Difficult Cannulation of Stenosed Pancreaticojejunostomy

Propofol Does Not Reduce Pyroptosis of Enterocytes and Intestinal Epithelial Injury After Lipopolysaccharide Challenge

Trans-splenic Embolization Plus Partial Splenic Embolization for Management of Variceal Bleeding Due to Left-Sided Portal Hypertension

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin